[go: up one dir, main page]

PE20060364A1 - Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen - Google Patents

Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen

Info

Publication number
PE20060364A1
PE20060364A1 PE2005000574A PE2005000574A PE20060364A1 PE 20060364 A1 PE20060364 A1 PE 20060364A1 PE 2005000574 A PE2005000574 A PE 2005000574A PE 2005000574 A PE2005000574 A PE 2005000574A PE 20060364 A1 PE20060364 A1 PE 20060364A1
Authority
PE
Peru
Prior art keywords
crystal form
procedure
contain
preparation
pharmaceutical compositions
Prior art date
Application number
PE2005000574A
Other languages
English (en)
Inventor
Stephane Horvath
Isabelle Demuynck
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060364(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20060364A1 publication Critical patent/PE20060364A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)

Abstract

SE REFIERE A UNA FORMA CRISTALINA ALFA DEL RANELATO DE ESTRONCIO DE FORMULA(I) O SAL DIESTRONCICA DEL ACIDO 5-[BIS(CARBOXIMETIL)AMINO]-3-CARBOXIMETIL-4-CIANO-2-TIOFENCARBOXILICO, CARACTERIZADA POR UN CONTENIDO EN AGUA ENTRE 22 Y EL 24%, Y PRESENTAR MEDIANTE UN MODELO DE DIFRACCION DE POLVO POR RAYOS X, UNO O MAS DE LOS SIGUIENTES PICOS: 7,6; 8,0; 8,3; 8,6; 8,9; 11,0; 11,3;12,0; 13,2; 13,5; 14,1; 14,7; 14,9; 15,8, ENTRE OTROS, EXPRESADOS EN GRADOS 2* (ANGULO DE BRAGS). TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION DE ESTA FORMA CRISTALINA Y UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE UTIL PARA LA PREVENCION Y TRATAMIENTO DE LA OSTEOPOROSIS
PE2005000574A 2004-09-30 2005-05-24 Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen PE20060364A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410335A FR2875807B1 (fr) 2004-09-30 2004-09-30 Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PE20060364A1 true PE20060364A1 (es) 2006-06-17

Family

ID=34942420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000574A PE20060364A1 (es) 2004-09-30 2005-05-24 Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen

Country Status (41)

Country Link
US (2) US7459568B2 (es)
EP (2) EP1944302A1 (es)
JP (2) JP2006104184A (es)
KR (1) KR100816590B1 (es)
CN (1) CN100391956C (es)
AP (1) AP1930A (es)
AR (1) AR049395A1 (es)
AT (1) ATE411308T1 (es)
AU (1) AU2005202718B2 (es)
BR (1) BRPI0502228A (es)
CA (1) CA2508824C (es)
CO (1) CO5710195A1 (es)
CR (1) CR7876A (es)
CY (1) CY1108797T1 (es)
DE (1) DE602005010359D1 (es)
DK (1) DK1642897T3 (es)
EA (1) EA008474B1 (es)
EC (1) ECSP055859A (es)
ES (1) ES2314593T3 (es)
FR (1) FR2875807B1 (es)
GE (1) GEP20074106B (es)
GT (1) GT200500130A (es)
HR (1) HRP20080652T3 (es)
IL (1) IL169237A (es)
MA (1) MA27815A1 (es)
MX (1) MXPA05006407A (es)
NO (1) NO333948B1 (es)
NZ (1) NZ540802A (es)
OA (1) OA13013A (es)
PA (1) PA8638201A1 (es)
PE (1) PE20060364A1 (es)
PL (1) PL1642897T3 (es)
PT (1) PT1642897E (es)
RS (1) RS51110B (es)
SA (1) SA05260168B1 (es)
SG (1) SG121035A1 (es)
SI (1) SI1642897T1 (es)
TW (1) TWI367881B (es)
UA (1) UA80008C2 (es)
WO (1) WO2006035122A1 (es)
ZA (1) ZA200504937B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
CN101206208B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析雷尼酸锶原料及其制剂的方法
CN102227419A (zh) * 2008-09-29 2011-10-26 拉蒂奥法姆有限责任公司 无水和水合形式的雷奈酸锶
IT1398542B1 (it) * 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en) 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) * 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
TW398975B (en) 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
PT1451194E (pt) * 2001-10-03 2007-01-31 Teva Pharma Preparação de hemi-hidrato de levofloxacina
AU2003223158B2 (en) * 2002-01-09 2008-01-17 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
US7396839B2 (en) * 2002-08-06 2008-07-08 Teva Pharmaceuticals Usa, Inc. Crystalline forms of gatifloxacin
FR2844795B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844796A1 (fr) 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
AP2005003323A0 (en) 2005-06-30
DE602005010359D1 (de) 2008-11-27
HRP20080652T3 (en) 2009-01-31
PA8638201A1 (es) 2006-05-16
HK1086260A1 (zh) 2006-09-15
JP2010132669A (ja) 2010-06-17
EA200500842A1 (ru) 2006-04-28
US7745482B2 (en) 2010-06-29
CA2508824A1 (fr) 2006-03-30
FR2875807A1 (fr) 2006-03-31
JP2006104184A (ja) 2006-04-20
DK1642897T3 (da) 2009-01-26
RS51110B (sr) 2010-10-31
IL169237A (en) 2010-12-30
GEP20074106B (en) 2007-05-10
TWI367881B (en) 2012-07-11
CO5710195A1 (es) 2006-12-29
CN1754878A (zh) 2006-04-05
OA13013A (fr) 2006-11-10
NO20052998L (no) 2006-03-31
EP1944302A1 (fr) 2008-07-16
AU2005202718B2 (en) 2010-09-16
ZA200504937B (en) 2006-04-26
US7459568B2 (en) 2008-12-02
CA2508824C (fr) 2009-03-24
PL1642897T3 (pl) 2009-04-30
AR049395A1 (es) 2006-07-26
SI1642897T1 (sl) 2009-02-28
MA27815A1 (fr) 2006-04-03
CR7876A (es) 2007-12-10
MXPA05006407A (es) 2006-04-05
UA80008C2 (uk) 2007-08-10
PT1642897E (pt) 2008-11-27
KR100816590B1 (ko) 2008-03-24
NZ540802A (en) 2006-11-30
SA05260168B1 (ar) 2009-02-25
EP1642897A1 (fr) 2006-04-05
US20080312314A1 (en) 2008-12-18
EA008474B1 (ru) 2007-06-29
AU2005202718A1 (en) 2006-04-13
AP1930A (en) 2008-12-15
US20060069271A1 (en) 2006-03-30
BRPI0502228A (pt) 2006-05-09
ECSP055859A (es) 2006-09-18
ES2314593T3 (es) 2009-03-16
CN100391956C (zh) 2008-06-04
CY1108797T1 (el) 2014-04-09
NO20052998D0 (no) 2005-06-17
KR20060049966A (ko) 2006-05-19
SG121035A1 (en) 2006-04-26
ATE411308T1 (de) 2008-10-15
TW200610758A (en) 2006-04-01
EP1642897B1 (fr) 2008-10-15
WO2006035122A1 (fr) 2006-04-06
FR2875807B1 (fr) 2006-11-17
GT200500130A (es) 2005-12-20
NO333948B1 (no) 2013-10-28
EP1642897B9 (fr) 2009-08-12

Similar Documents

Publication Publication Date Title
PE20060364A1 (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
CL2008001194A1 (es) Composicion farmaceutica que comprende florfenico, una ciclodextrina y agua, un solvente y7o una mezcka de los mismos, con al menos 5% de solvente; kit que la contiene; complejo de florfenicol, util para tratr enfermedades respiratorias en animales
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
BRPI0621386B8 (pt) composição farmacêutica para o uso externo
BRPI0710485B8 (pt) composições líquidas úteis no tratamento de doenças respiratórias
CO6260128A2 (es) Composiciones de hipoclorito de calcio que contienen sales de zinc y cal
GT201200192A (es) Composición acuosa antitranspirante / desodorante
PE20071310A1 (es) Formulaciones liquidas de fenilefrina
PE20051131A1 (es) COMPOSICIONES ANTIPERSPIRANTES CON pH ELEVADO DE EFICACIA MEJORADA
CL2012003009A1 (es) Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct.
PE20091312A1 (es) Producto para el cuidado oral y metodos de uso y fabricacion de los mismos
RU2008139905A (ru) Фармацевтическая композиция для наружного применения
ES2570599T3 (es) Composición suave para desinfección cutánea
RU2013151904A (ru) Применение соединений мышьяка для лечения отторжения ткани или органа
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
MY151295A (en) Pyrimidyl indoline compound
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
AR079050A1 (es) Compuestos benzoimidazolicos y sus usos
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
CL2008001605A1 (es) Una formulacion de dosis intranasal que comprende asenapina o una sal farmaceuticamente aceptable y un portador liquido que contiene agua y un poliol, util para el tratamiento de la esquizofrenia.
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
BRPI0519605A2 (pt) composiÇÕes de cuidado pessoal
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed